Entries by Russell Radefeld

Kindred Biosciences Receives Approval of Effectiveness Technical Section from FDA for Zimeta New Animal Drug Application

San Francisco, CA (October 4, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced it has received a technical section complete letter for effectiveness from the U.S. Food and Drug Administration’s Center for Veterinary Medicine for Zimeta™ (dipyrone injection) approving the technical section. The […]

Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Mirataz to FDA and Launches KindredBio Equine Website

San Francisco, CA (September 30, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Mirataz™ (mirtazapine 2% transdermal ointment, KIND-010).  This is the final major technical section […]

KindredBio supports New Horizon Ranch – both working to strengthen the bond between horses and humans

KindredBio is a veterinary biopharmaceutical company based in Burlingame, CA that is focused on a strong development pipeline serving the horse with the motto “best medicines for our best friends.” KindredBio’s co-founder and many employees are horse people and advocates for the bond between horses and people with an understanding of how these animals change […]

Kindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference

San Francisco, CA (September 20, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced Dr. Richard Chin, President and CEO, will be presenting at the Ladenburg Thalmann Healthcare Conference in New York City on Tuesday, September 27, 2016 at 11:00 AM EDT. The conference is […]